Lazard Asset Management LLC Denali Therapeutics Inc. Transaction History

Lazard Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $104,506 - $149,534	-6,451 Reduced 59.4%	4,410 $94,000
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $122,047 - $178,485	5,916 Added 119.64%	10,861 $224,000
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $47,324 - $66,744	2,025 Added 69.35%	4,945 $145,000
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $53,307 - $79,486	-2,433 Reduced 45.45%	2,920 $67,000
Q2 2022 Aug 09, 2022	BUY	$20.88 - $35.19 $111,770 - $188,372	5,353 New	5,353 $157,000
Q4 2021 Feb 09, 2022	SELL	$42.59 - $55.02 $50,511 - $65,253	-1,186 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $57,497 - $92,780	1,186 New	1,186 $59,000
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $41,899 - $65,340	-833 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $44,815 - $67,914	833 New	833 $47,000
Q1 2020 May 14, 2020	SELL	$14.2 - $27.98 $15,236 - $30,022	-1,073 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$14.4 - $19.99 $15,451 - $21,449	1,073 New	1,073 $18,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.